Dynavax Technologies Co. Expected to Post Q4 2023 Earnings of $0.00 Per Share (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) – Investment analysts at HC Wainwright increased their Q4 2023 earnings estimates for shares of Dynavax Technologies in a research report issued to clients and investors on Monday, September 18th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will post earnings of $0.00 per share for the quarter, up from their previous estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for Dynavax Technologies’ FY2024 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Several other equities analysts have also commented on DVAX. StockNews.com initiated coverage on Dynavax Technologies in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. JMP Securities upped their target price on shares of Dynavax Technologies from $24.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, August 4th.

Dynavax Technologies Trading Down 0.6 %

DVAX opened at $13.57 on Tuesday. The business’s 50 day moving average price is $14.19 and its 200 day moving average price is $12.22. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.59 and a current ratio of 17.78. The stock has a market capitalization of $1.75 billion, a PE ratio of 18.85 and a beta of 1.52. Dynavax Technologies has a one year low of $9.42 and a one year high of $15.12.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. The business had revenue of $60.25 million during the quarter, compared to analysts’ expectations of $51.03 million. Dynavax Technologies had a net margin of 24.08% and a return on equity of 19.91%.

Insiders Place Their Bets

In related news, COO David F. Novack sold 20,000 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $14.48, for a total value of $289,600.00. Following the sale, the chief operating officer now owns 3,187 shares in the company, valued at approximately $46,147.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CMO Robert Janssen sold 2,600 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $15.05, for a total transaction of $39,130.00. Following the completion of the transaction, the chief marketing officer now directly owns 49,925 shares in the company, valued at approximately $751,371.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO David F. Novack sold 20,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $14.48, for a total value of $289,600.00. Following the transaction, the chief operating officer now owns 3,187 shares of the company’s stock, valued at $46,147.76. The disclosure for this sale can be found here. Insiders have sold 1,605,518 shares of company stock worth $23,148,941 over the last ninety days. Corporate insiders own 2.62% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in Dynavax Technologies by 1.6% during the 2nd quarter. BlackRock Inc. now owns 19,183,847 shares of the biopharmaceutical company’s stock valued at $247,855,000 after acquiring an additional 307,793 shares during the period. State Street Corp boosted its stake in shares of Dynavax Technologies by 19.1% in the 3rd quarter. State Street Corp now owns 10,274,230 shares of the biopharmaceutical company’s stock valued at $107,263,000 after buying an additional 1,644,803 shares during the period. Vanguard Group Inc. boosted its stake in shares of Dynavax Technologies by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 8,165,641 shares of the biopharmaceutical company’s stock valued at $85,249,000 after buying an additional 141,674 shares during the period. Deep Track Capital LP boosted its stake in shares of Dynavax Technologies by 3.3% in the 2nd quarter. Deep Track Capital LP now owns 6,557,816 shares of the biopharmaceutical company’s stock valued at $84,727,000 after buying an additional 207,816 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Dynavax Technologies by 811.6% in the 1st quarter. Bank of America Corp DE now owns 4,340,287 shares of the biopharmaceutical company’s stock valued at $42,578,000 after buying an additional 3,864,170 shares during the period. 99.13% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.